Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares have been powering on, with a gain of 26% in the last thirty days. Looking back a bit further, it’s encouraging to see the stock is up 48% in the last year.
Although its price has surged higher, Teva Pharmaceutical Industries may still be sending very bullish signals at the moment with its price-to-sales (or “P/S”) ratio of 1.7x, since almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 4x and even P/S higher than 17x are not unusual. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
